Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT01813383
NCT01813383CompletedNot Applicable

Clinical Relevance of Typing HLA-DR7-DQ2

Corporacion Parc Tauli1 site in 1 country92 target enrollmentStarted: January 2010Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
92
Locations
1
Primary Endpoint
Anti-tissue transglutaminase
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

Celiac disease patients with HLA-DR7-DQ2 haplotype have the same histological, analytical and clinical behaviour as patients with HLA-DR3-DQ2 haplotype.

Study Design

Study Type
Observational
Observational Model
Case Only
Time Perspective
Prospective

Eligibility Criteria

Ages
— to 18 Years (Child, Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Diagnosis of celiac disease following ESPGHAN recommendations
  • •HLA-DQ2 typing including HLA-DR3-DQ2 and HLA-DR7-DQ2 haplotypes

Exclusion Criteria

  • •Patients who have not been diagnosed for celiac disease
  • •HLA-DQ2 typing that not include HLA-DR7-DQ2 haplotype

Outcomes

Primary Outcomes

Anti-tissue transglutaminase

Time Frame: Up to 1 month after diagnosis

Secondary Outcomes

  • Anti-Endomysium autoantibodies(Up to 1 month after diagnosis)

Investigators

Sponsor
Corporacion Parc Tauli
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Juan Francisco Delgado de la Poza

Medicine. Immunology specialist

Corporacion Parc Tauli

Study Sites (1)

Loading locations...

Similar Trials

Enrolling By Invitation
Not Applicable
"Adding DNA-test for Screening of HLA-DQ2 and DQ8 to Improve Early Diagnosis of Celiac Disease"Celiac Disease in Children
NCT06179121Leiden University Medical Center508
Completed
Phase 2
HLA-DQ2-gliadin Tetramer for Diagnosis of Celiac DiseaseGlutenCeliac Disease
NCT01100099Oslo University Hospital100
Unknown
Not Applicable
Polymorphisms of Interleukins, Glypican, and Human Leukocyte Antigen Genes and Treatment Response in Multiple Sclerosis.Multiple Sclerosis, Relapsing-Remitting
NCT02769767Instituto Jalisciense de Cancerologia500
Completed
Phase 2
Matched Unrelated or Non-Genotype Identical Related Donor Transplantation For Chronic Granulomatous DiseaseChronic Granulomatous Disease
NCT00578643Baylor College of Medicine15
Completed
Not Applicable
Quantitative Parameters of HLA-DQ Antibodies in Lung TransplantationLung TransplantationAntibody Mediated RejectionChronic Lung Allograft Dysfunction
NCT03474536University Hospital, Bordeaux88